GLP-1 Weight Loss: How Do I Compare With the Trials?

Your data never leaves your browser

The selection is only used for the comparison and never leaves your browser.

The calculator uses your trend weight from the start date on. The starting weight above stays the reference point.

Order and separators don't matter, comma or dot as decimal mark. Several weigh-ins on the same day are averaged.

Drop a file here or

Apple Health (export.zip or export.xml), Withings (weight.csv or ZIP), Google Fit (Takeout CSV), Happy Scale, Libra, openScale, Trendcurve and any CSV with a date and a weight column.

Where you stand

Your change
Since start
Trial mean at endpoint
Placebo at endpoint
Your course Trial mean (dots verified, line interpolated) Placebo (dots verified, line interpolated)

Please note
  • Not medical advice: the calculator compares numbers, it does not assess your treatment or your health.
  • Trial means describe groups of hundreds of people over 68 or 72 weeks, with diet and activity counselling. Individual courses vary widely, in both directions.
  • No dosing advice: your doctor decides on the dose and how it is increased. Do not change anything because of this comparison.
  • The value used is the one for all randomised participants (treatment-policy or treatment-regimen estimand), including those who stopped treatment.

The trial values at a glance

Mean change in body weight from baseline at the endpoint and share of participants with at least 5, 10, 15 and 20 percent weight loss.

Arm Week Mean Placebo At least 5 / 10 / 15 / 20 % loss
Semaglutide 2.4 mg (STEP 1) 68 −14.9 % −2.4 % 86.4 % / 69.1 % / 50.5 % / 32.0 %
Placebo: 31.5 % / 12.0 % / 4.9 % / 1.7 %
Tirzepatide 5 mg (SURMOUNT-1) 72 −15.0 % −3.1 % 85.1 % / 68.5 % / 48.0 % / 30.0 %
Placebo: 34.5 % / 18.8 % / 8.8 % / 3.1 %
Tirzepatide 10 mg (SURMOUNT-1) 72 −19.5 % −3.1 % 88.9 % / 78.1 % / 66.6 % / 50.1 %
Placebo: 34.5 % / 18.8 % / 8.8 % / 3.1 %
Tirzepatide 15 mg (SURMOUNT-1) 72 −20.9 % −3.1 % 90.9 % / 83.5 % / 70.6 % / 56.7 %
Placebo: 34.5 % / 18.8 % / 8.8 % / 3.1 %

STEP 1: 1,961 participants with a BMI of 30 or more (or 27 or more with a weight-related condition) without diabetes, mean baseline weight 105.3 kg. Shares: participants with data at week 68.

SURMOUNT-1: 2,539 participants with a BMI of 30 or more (or 27 or more with a weight-related condition) without diabetes, mean baseline weight 104.8 kg. Values from the US prescribing information (Study 1).

Sources

  1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. doi.org/10.1056/NEJMoa2032183 · PubMed
  2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216. doi.org/10.1056/NEJMoa2206038 · PubMed
  3. Wegovy (semaglutide) injection, US Prescribing Information, FDA 2021, Table 4. www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000Lbl.pdf
  4. Zepbound (tirzepatide) injection, US Prescribing Information, FDA 2023, Table 3 (Study 1 = SURMOUNT-1). www.accessdata.fda.gov/drugsatFDA_docs/label/2023/217806s000lbl.pdf